Approved and unapproved use of immunoglobulins in Iceland - 30/05/13
Disclosure of potential conflict of interest: G. Gröndal has received one or more payments for travel/accommodations/meeting expenses from MSD and Pfizer. Á. Haraldsson has received one or more grants from or has one or more grants pending with GSK (pneumococcal research), has received one or more payments for lecturing from or is on the speakers' bureau for GSK and Pfizer (pneumococcus and vaccination), and has received one or more payments for travel/accommodations/meeting expenses from GSK, AstraZeneca, and CSL Behring. B. R. Lúðvíksson has received one or more payments for travel/accommodations/meeting expenses from AstraZeneca, Pfizer, Phadia, and CSL Berhing. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 131 - N° 6
P. 1703-1705 - juin 2013 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?